Future prospects for mitosis-targeted antitumor therapies

Serrano-del Valle A. ; Reina-Ortiz C. ; Benedi A. (Universidad de Zaragoza) ; Anel A. (Universidad de Zaragoza) ; Naval J. (Universidad de Zaragoza) ; Marzo I. (Universidad de Zaragoza)
Future prospects for mitosis-targeted antitumor therapies
Resumen: Dysregulation of cell cycle progression is a hallmark of cancer cells. In recent years, efforts have been devoted to the development of new therapies that target proteins involved in cell cycle regulation and mitosis. Novel targeted antimitotic drugs include inhibitors of aurora kinase family, polo-like kinase 1, Mps1, Eg5, CENP-5 and the APC/cyclosome complex. While certain new inhibitors reached the clinical trial stage, most were discontinued due to negative results. However, these therapies should not be readily dismissed. Based on recent advances concerning their mechanisms of action, new strategies could be devised to increase their efficacy and promote further clinical trials. Here we discuss three main lines of action to empower these therapeutic approaches: increasing cell death signals during mitotic arrest, targeting senescent cells and facilitating antitumor immune response through immunogenic cell death (ICD). © 2021 The Author(s)
Idioma: Inglés
DOI: 10.1016/j.bcp.2021.114655
Año: 2021
Publicado en: Biochemical Pharmacology 190 (2021), 114655 [13 pp]
ISSN: 0006-2952

Factor impacto JCR: 6.1 (2021)
Categ. JCR: PHARMACOLOGY & PHARMACY rank: 46 / 279 = 0.165 (2021) - Q1 - T1
Factor impacto CITESCORE: 9.3 - Pharmacology, Toxicology and Pharmaceutics (Q1) - Biochemistry, Genetics and Molecular Biology (Q1)

Factor impacto SCIMAGO: 1.24 - Pharmacology (Q1) - Biochemistry (Q1)

Financiación: info:eu-repo/grantAgreement/ES/MINECO/SAF2016-76338-R
Tipo y forma: Article (Published version)
Área (Departamento): Área Bioquímica y Biolog.Mole. (Dpto. Bioq.Biolog.Mol. Celular)
Área (Departamento): Área Biología Celular (Dpto. Bioq.Biolog.Mol. Celular)

Creative Commons You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Exportado de SIDERAL (2023-05-18-15:46:56)

Este artículo se encuentra en las siguientes colecciones:

 Record created 2022-07-05, last modified 2023-05-19

Versión publicada:
Rate this document:

Rate this document:
(Not yet reviewed)